Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Chronic kidney disease? 211 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 211 reports of Chronic kidney disease have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.1% of all adverse event reports for TOFACITINIB.

211
Reports of Chronic kidney disease with TOFACITINIB
0.1%
of all TOFACITINIB reports
11
Deaths
39
Hospitalizations

How Dangerous Is Chronic kidney disease From TOFACITINIB?

Of the 211 reports, 11 (5.2%) resulted in death, 39 (18.5%) required hospitalization, and 3 (1.4%) were considered life-threatening.

Is Chronic kidney disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 211 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Chronic kidney disease?

OMEPRAZOLE (35,759) ESOMEPRAZOLE (35,281) LANSOPRAZOLE (32,517) PANTOPRAZOLE (28,127) DEXLANSOPRAZOLE (15,973) EMTRICITABINE\TENOFOVIR DISOPROXIL (10,248) TENOFOVIR DISOPROXIL (7,230) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (5,861) RABEPRAZOLE (4,773) ESOMEPRAZOLE\NAPROXEN (2,714)

Which TOFACITINIB Alternatives Have Lower Chronic kidney disease Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Chronic kidney disease Reports All Drugs Causing Chronic kidney disease TOFACITINIB Demographics